Rehovots' XTL Biopharmaceuticals Ltd. to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
Contacts: XTLbio, Jonathan Burgin, Chief Financial Officer, tel: (972-8) 930-4440
About XTL Biopharmaceuticals Ltd. Established in 1993, XTL Biopharmaceuticals Ltd. (LSE: XTL; NASDAQ: XTLB; TASE: XTL) is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of infectious diseases, particularly the prevention and treatment of hepatitis B and C.
Cautionary Statement. Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the US Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially, and therefore affect interest by investors in our securities, are the following: the results of prior trails with XTL-686are not necessarily indicative of the results we may have in the Phase 1a and 1b trials; and other risk factors identified from time to time in our reports filed with the various regulatory bodies. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only."
Source: Rehovots' XTL Biopharmaceuticals Ltd. to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. PRNewswire-FirstCall (3 November 2005) [FullText]
0 Comments:
Post a Comment
<< Home